Vaccines against Brucella abortus, B. melitensis and B. suis have been based on weakened or killed bacteria, however there is no recombinant vaccine for disease prevention or therapy. This study attempted to predict IFN-γ epitopes, T cell cytotoxicity, and T lymphocytes in order to produce a multiepitope vaccine based on BtpA, Omp16, Omp28, virB10, Omp25, and Omp31 antigens against B. melitensis, B. abortus, and B. suis. AAY, GPGPG, and EAAAK peptides were used as epitope linkers, while the PADRE sequence was used as a Toll-like receptor 2 (TLR2) and TLR4 agonist. The final construct included 389 amino acids, and was a soluble protein with a molecular weight of 41.3 kDa, and nonallergenic and antigenic properties. Based on molecular docking studies, molecular dynamics simulations such as Gyration, RMSF, and RMSD, as well as tertiary structure validation methods, the modeled protein had a stable structure capable of interacting with TLR2/4. As a result, this novel vaccine may stimulate immune responses in B and T cells, and could prevent infection by B. suis, B. abortus, and B. melitensis.

流产布鲁氏菌疫苗，B 。melitensis和B . suis是基于减弱或杀死的细菌，但是没有用于疾病预防或治疗的重组疫苗。本研究试图预测 IFN-γ 表位、T 细胞细胞毒性和 T 淋巴细胞，以生产基于针对B的 BtpA、Omp16、Omp28、virB10、Omp25 和 Omp31 抗原的多表位疫苗。苜蓿，B . 流产，和B。猪. AAY、GPPGG 和 EAAAK 肽用作表位接头，而 PADRE 序列用作 Toll 样受体 2 (TLR2) 和 TLR4 激动剂。最终构建体包含 389 个氨基酸，是一种可溶性蛋白质，分子量为 41.3 kDa，具有非过敏性和抗原性。基于分子对接研究、Gyration、RMSF和RMSD等分子动力学模拟，以及三级结构验证方法，模型蛋白具有能够与TLR2/4相互作用的稳定结构。因此，这种新型疫苗可能会刺激 B 和 T 细胞的免疫反应，并可以预防B感染。苏斯，B . 流产，和B。苜蓿_